The average 12-month price target for Kinnate Biopharma has decreased by 9.96% from the previous average, which may indicate a change in analysts' outlook on the stock. However, the overall sentiment remains positive with 5 bullish ratings, 2 somewhat bullish ratings, and 2 indifferent ratings. The short-term impact on the stock price is neutral as the decrease in the average price target is not significant enough to cause a major shift in investor sentiment.